Colgate-Palmolive Stock: Is CL Outperforming the Consumer Defensive Sector?

Colgate-Palmolive Company (CL), headquartered in New York, is a global consumer products company focused on Oral Care, Personal Care, Home Care, and Pet Nutrition. With a history spanning over 200 years, the company sells trusted health and hygiene products in more than 200 countries and territories worldwide. It has a market capitalization of $71.8 billion.

Companies worth $10 billion to $200 billion are generally described as “large-cap stocks,” and Colgate-Palmolive fits that description, with its market cap exceeding this threshold and reflecting its substantial size, influence, and dominance in the consumer defensive sector. It benefits from strong global leadership across oral care, personal care, home care, and pet nutrition, backed by trusted brands and established distribution networks. Its geographic diversification, productivity programs, strong gross margins, and long-standing dividend growth provide resilience while supporting investment in its brands and future growth.

CL has slipped 9.3% from its 52-week high of $99.33, reached on February 27, 2026. Over the past three months, CL stock has climbed 6.2%, outperforming the State Street Consumer Staples Select Sector SPDR ETF (XLP), which has gained 3.8% over the same period.

The same trend continues in the long term as well. Shares of CL have gained 14% year-to-date and 7.5% over the past 52 weeks, outperforming XLP’s 9.8% YTD gain and 5.8% return over the past year.

While CL has been trading above its 200-day moving average since late April, it dipped below the 50-day moving average in late August. 

CL has outperformed the broader market, supported by resilient financial performance, strong profitability, and its well-established brands. Its long-standing dividend growth also makes the stock attractive to income-focused investors.

On Aug. 3, however, Colgate-Palmolive’s shares declined 1.6% following the release of its Q2 FY2026 earnings. Although revenue increased 4.9% year over year to $5.4 billion and adjusted EPS of $0.99 surpassed Wall Street’s expectations, the company’s operating margin fell from 21.1% to 19%.

In the competitive consumer defensive sector, top rival The Procter & Gamble Company (PG) has considerably underperformed CL, with a 2.5% gain year-to-date and a 7.1% decline over the past 52 weeks.

Wall Street analysts are somewhat bullish on CL’s prospects. The stock has a consensus “Moderate Buy” rating from the 22 analysts covering it. The mean price target of $98.09 suggests potential upside of 8.9% from current price levels.

On the date of publication, Kritika Sarmah did not have (either directly or indirectly) positions in any of the securities mentioned in this article. All information and data in this article is solely for informational purposes. For more information please view the Barchart Disclosure Policy here.